SCHEMBL2864303

SCHEMBL2864303

Nc1c2c(=O)[nH]c3ccc(OCCCN4CCOCC4)cc3c2nn1-c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.48
PDGFRB P09619 1/20 0.48
KDR P35968 1/20 0.48
PARP1 P09874 1/20 0.44
KDM4E B2RXH2 3/20 0.43
RAF1 P04049 1/20 0.42
MAP2K1 Q02750 1/20 0.42
SRC P12931 2/20 0.42
SIGMAR1 Q99720 3/20 0.42
CSF1R P07333 1/20 0.42
BTK Q06187 1/20 0.41
EPHX2 P34913 1/20 0.41
HRH2 P25021 1/20 0.40
HRH1 P35367 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857971 0.94 FGFR1 (0.48) FGFR1PDGFRBKDRKDM4ERAF1
SCHEMBL2861080 0.91 FGFR1 (0.55) FGFR1PDGFRBKDRPARP1KDM4E
SCHEMBL2860241 0.88 MAP2K1 (0.48) KDRKDM4ERAF1MAP2K1SRC
SCHEMBL2857668 0.86 HRH4 (0.45) KDM4ESIGMAR1HRH3ADORA2AADORA1
SCHEMBL2866809 0.85 MCHR1 (0.51) FGFR1PDGFRBKDRKDM4ESRC
SCHEMBL2865355 0.85 FGFR1 (0.43) FGFR1PDGFRBKDRKDM4ERAF1
SCHEMBL2870417 0.85 PDGFRB (0.43) FGFR1PDGFRBKDRKDM4ERAF1
SCHEMBL2861085 0.84 MAOA (0.42) FGFR1PDGFRBKDRPARP1KDM4E
SCHEMBL2869046 0.84 RAF1 (0.47) FGFR1PDGFRBKDRKDM4ERAF1
SCHEMBL2865177 0.84 FGFR1 (0.45) FGFR1PDGFRBKDRPARP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 FGFR1 201/4885PDGFRB 375/4885KDR 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.